$1.45
+0.10 (+7.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VANI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 2 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP) · FINRA short interest 2.2 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059Area under the plasma concentration-time curve (AUC)Randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Combination product: Semaglutide Implant (NPM-139) · Drug: Semaglutide (Wegovy) weekly injection | Obesity & Overweight | 20 | Dec 2026 | ≤ 134 d | 2026-06-30 |
| Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantNCT05670379Area under the plasma concentration-time curve (AUC)Randomized · Open-label · Treatment | Phase 1 | Completed | Combination product: Exenatide Implant · Drug: Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL | Overweight and Obesity, Type2diabetes | 24 | 2025-08-21actual | — | 2025-09-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19